Polypeptides, derivatives and uses thereof

Details Polypeptides, derivatives and uses thereof Polypeptides, derivatives and uses thereof

2002-04-17

2009-11-24

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S017400, C530S300000, C530S330000, C530S331000, C530S333000, C530S345000

Reexamination Certificate

active

07622446

ABSTRACT:
The invention provides a compound having formula X1-Arg-Xaa-Arg-X2in which X1and X2are up to 30 amino acid residues and Xaa is an amino acid residue. A preferred compound is the tripeptide Arg-Glu-Arg which corresponds to amino acid residues 328 to 330 of human amyloid precursor protein. The invention further provides a derivative of a polypeptide having the formula: X1-Arg-Xaa-Arg-X2wherein X1and X2, which may be the same or different, each represents from zero to 30 natural or synthetic amino acid residues or derivatives thereof and Xaa represents a natural or synthetic amino acid residue or derivative thereof, at least one functional group of at least one said amino acid residue or derivative thereof being protected by a protective group. The compounds of the invention are believed to be useful in the treatment of Alzheimer's disease and as cognitive enhancers.

REFERENCES:
patent: 660483 (1900-10-01), Feige et al.
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4061736 (1977-12-01), Morris et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4565804 (1986-01-01), Rivier et al.
patent: 4707468 (1987-11-01), Yoshino et al.
patent: 4810636 (1989-03-01), Corey
patent: 5028592 (1991-07-01), Lipton
patent: 5493008 (1996-02-01), Fox et al.
patent: 5597569 (1997-01-01), Siegall et al.
patent: 5639726 (1997-06-01), Lawrence et al.
patent: 5777083 (1998-07-01), Burnie et al.
patent: 5958883 (1999-09-01), Snow
patent: 6126939 (2000-10-01), Eisenbach-Schwartz et al.
patent: 6214797 (2001-04-01), Vale et al.
patent: 2003/0032593 (2003-02-01), Wender et al.
patent: 2003/0166529 (2003-09-01), Mileusnic et al.
patent: 58-183656 (1983-10-01), None
patent: WO94/09808 (1994-05-01), None
patent: WO97/00063 (1997-01-01), None
patent: WO 97/04748 (1997-02-01), None
patent: WO98/09985 (1998-03-01), None
patent: WO98/21327 (1998-05-01), None
patent: WO99/57305 (1999-11-01), None
patent: WO 99/58564 (1999-11-01), None
patent: WO 99/67284 (1999-12-01), None
patent: WO 00/06900 (2000-11-01), None
D.A. Kirby, et al. J. Med. Chem. (1995) 38, pp. 4579-4586.
“Derivative” The On-ine Medical Dictionary. entered Nov. 18, 1997. Accessed Jul. 7, 2005. <http://cancerweb.ncl.ac.uk>> 3 pages.
Abe, et al.; “Administration of amyloid β-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo”;Brain Research636:162-164 (1994).
Barnes, et al.; “Increased Production of Amyloid Precursor Protein Provides a Substrate for Caspase-3 in Dying Motoneurons”;The Journal of Neuroscience18(15):5869-5880 (Aug. 1, 1998).
Cleary, et al.; “Beta-amyloid (1-40) effects on behavior and memory”;Brain Research682:69-74 (1995).
Coulson, et al.; “What the evolution of the amyloid protein precursor supergene family tells us about its function”;Neurochemistry International36:175-184 (2000).
Curtain, et al.:“Fusogenic activity of amino-terminal region of HIV type 1 Nef protein”Aids Research And Human Retroviruses10(10):1231-40 (Oct. 1994).
Davis, et al.; “Autoradiographic Distribution of L-Proline in Chicks After Intracerebral Injection”;Physiology&Behavior22:693-695 (1979).
Doyle, et al.; “Intraventricular infusions of antibodies to amyloid-β-protein precursor impair the acquisition of a passive avoidance response in the rat”;Neuroscience Letters115 97-102 (1990).
Flood, et al.; “Amnestic effects in mice of four synthetic peptides homologous to amyloid β protein from patients with Alzheimer disease”;Proc. Natl. Acad. Sci. USA88:3363-3366 (Apr. 1991).
Goodman, et al.; “Secreted Forms of β-Amyloid Precursor Protein Protect Hippocampal Neurons against Amyloid β-Peptide-Induced Oxidative Injury”;Experimental Neurology128:1-12 (1994).
Goodman, et al.; “K+ channel openers protect hippocampal neurons against oxidative injury and amyloid β-peptide toxicity”;Brain Research706:328-332 (1996).
Huber, et al.; “Synaptic β-Amyloid Precursor Proteins Increase with Learning Capacity in Rats”;Neuroscience80(2):313-320 (1997).
Huber, et al.; “Involvement of amyloid precursor protein in memory formation in the rat: an indirect antibody approach”;Brain Research603:348-352 (1993).
Ishida, et al.; “Secreted form of β-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices”;Neuro Report8:2133-2137 (1997).
James, et al.: “Basic amino acids predominate in the sequential autoantigenic determinant of the small nuclear 70K ribonucleoprotein”,Scandinavian Journal Of Immunology39(6):557-66 (1994).
Koo, et al., “Amyloid β-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth”,Proc. Natl. Acad. Sci. USA90:4748-4752 (May 1993).
Jin, et al.; “Peptides Containing the RERMS Sequence of Amyloid β/A4 Protein Precursor Bind Cell Surface and Promote Neurite Extension”;The Journal of Neuroscience14(9): 5461-5470 (Sep. 1994).
Kang, et al.; “The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor”;Nature325(19) (Feb. 1987).
LeBlanc, et al.; “Role of Amyloid Precursor Protein (APP): Study with Antisense Transfection of Human Neuroblastoma Cells”;Journal of Neuroscience Research31:635-645 (1992).
Li, et al.; “Defective Neurite Extension Is Caused by a Mutation in Amyloid β/A4 (Aβ) Protein Precursor Found in Familial Alzheimer's Disease”;J. Neurobiol.32:469-480 (1997).
Lossner, et al.; “Passive Avoidance Training Increases Fucokinase Activity in Right Forebrain Base of Day-Old Chicks”;Journal of Neurochemistry,41:1357-1363 (1983).
Mattson, et al.; “β-Amyloid precursor protein metabolites and loss of neuronal Ca2+homeostasis in Alzheimer's disease”;TINS16(10) (1993).
Mattson, et al.; “Evidence for Excitoprotective and Intraneuronal Calcium-Regulating Roles for Secreted Forms of the β-Amyloid Precursor Protein”;Neuron10:243-254 (Feb. 1993).
Mattson, Mark P.; “Secreted Forms of β-Amyloid Precursor Protein Modulate Dendrite Outgrowth and Calcium Responses to Glutamate in Cultured Embryonic Hippocampal Neurons”;J. Neurobiol.25:439-450 (1994).
Maurice, et al.; “Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction”;Brain Research706:181-193 (1996).
Merrifield, B: “Solid Phase Synthesis”Science,American Association For the Advancement Of Science, US, 232(18)341-347 (Apr. 18, 1986).
Meziane, et al.; “Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice”;Proc. Natl. Acad. Sci. USA95:12683-12688 (Oct. 1998).
Mileusnic, et al.; “APP is required during an early phase of memory formation”;European Journal of Neuroscience12:4487-4495 (2000).
Mucke, et al.; “Synaptotrophic effects of human amyloid β protein precursors in the cortex of transgenic mice”;Brain Research666:151-167 (1994).
Muller, et al.; “Behavioral and Anatomical Deficits in Mice Homozygous for a Modified β-Amyloid Precursor Protein Gene”;Cell79:755-765 (Dec. 2, 1994).
Multhaup, et. al.; “Characterization of the High Affinity Heparin Binding Site of the Alzheimer's Disease βA4 Amyloid Precursor Protein (APP) and its Enhancement by Zinc(II)”;Journal of Molecular Recognition8:247-257 (1995).
Ninomiya, et al.; “Amino Acid Sequence RERMS Represents the Active Domain of Amyloid β/A4 Protein Precursor that Promotes Fibroblast Growth”;The Journal of Cell Biology,121(4): 879-886 (May 1993).
Rist et al: “The bioactive conformation of neuropeptide Y analogues at the human Y-2-receptor”,European Journal Of Biochemistry247(3)1019-1028 (1997).
Roch, et al.; “Increa

Affiliated with

Also associated with

Rating

Polypeptides, derivatives and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polypeptides, derivatives and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides, derivatives and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4121835